Management will be available for meetings during this luncheon and
networking event
SAN FRANCISCO--(BUSINESS WIRE)--May 25, 2017--
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health
company focused on developing and commercializing first-in-class
gastrointestinal products for companion and production animals, foals,
and high value horses, and Napo Pharmaceuticals, Inc. (Napo), a human
health company developing and commercializing novel gastrointestinal
prescription products from plants used traditionally in rainforest
areas, announced today that Lisa Conte, Jaguar’s president and CEO and
Napo’s interim CEO, is scheduled to present at the Southern California
Investment Forum luncheon and networking gathering taking place 1:00pm –
4:00pm Pacific time on Wednesday, May 31st at the Skylight Gardens
Restaurant, Bar & Gallery in Los Angeles. Ms. Conte will be available
for one-on-one meetings with new and existing analysts, investors and
partners at the event. To register to attend the event, visit southerncaliforniainvestmentforum.com.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. focuses on the
development and commercialization of proprietary pharmaceuticals from
rainforest resources for the global marketplace in collaboration with
local partners. In April 2017, Napo launched Mytesi®, which
is approved by the U.S. FDA for the symptomatic relief of noninfectious
diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer,
the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals, foals, and high value horses.
Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea in
dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and
Neonorm™ Foal are the Company’s lead non-prescription
products. Neonorm™ is a standardized botanical extract
derived from the Croton lechleri tree. Canalevia™ and
Neonorm™ are distinct products that act at the same last step
in a physiological pathway generally present in mammals. Jaguar has nine
active investigational new animal drug applications, or INADs, filed
with the FDA and intends to develop species-specific formulations of
Neonorm™ in six additional target species, formulations of
Equilevia™ in horses, and Canalevia™ for cats and
dogs.
For more information about Jaguar, please visit jaguaranimalhealth.com.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for
the symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is
not indicated for the treatment of infectious diarrhea. Rule out
infectious etiologies of diarrhea before starting Mytesi®.
If infectious etiologies are not considered, there is a risk that
patients with infectious etiologies will not receive the appropriate
therapy and their disease may worsen. In clinical studies, the most
common adverse reactions occurring at a rate greater than placebo were
upper respiratory tract infection (5.7%), bronchitis (3.9%), cough
(3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a
botanical (plant-based) drug extracted and purified from the red bark
sap of the medicinal Croton lechleri tree in the Amazon
rainforest. Napo has established a sustainable harvesting program for
crofelemer to ensure a high degree of quality and ecological integrity.
Proposed Merger
As announced March 31, 2017, Napo and Jaguar have entered a definitive
merger agreement. The companies underscore their expectation that the
merger will close by the end of July, 2017.
Jaguar has filed with the SEC a Registration Statement on Form S-4 that
includes proxy solicitation materials. Stockholders of Jaguar and Napo
are urged to read the proxy solicitation/prospectus contained in the
Registration Statement when it becomes available and any other relevant
materials filed with the SEC because these materials will contain
important information about the potential merger.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the proposed merger of
Jaguar and Napo, the expectation that the proposed merger will close by
the end of July 2017, Jaguar’s intention to develop species-specific
formulations of Neonorm™ in additional target species, and
Jaguar’s plan to develop formulations of Canalevia™ for cats,
horses and dogs. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,” “plan,”
“aim,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this release are only predictions.
Jaguar has based these forward-looking statements largely on its current
expectations and projections about future events. These forward-looking
statements speak only as of the date of this release and are subject to
a number of risks, uncertainties and assumptions, some of which cannot
be predicted or quantified and some of which are beyond Jaguar’s
control. Except as required by applicable law, Jaguar does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20170525005484/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
